TKMR up +5.12% percent Today $TKMR High is at 17.2
Post# of 74
Posted On: 11/17/2014 12:08:11 PM
TKMR up +5.12% percent Today $TKMR High is at 17.26 and the Low 16.71 with current volume of 268,111.
Recent News posted below.
Tekmira Pharmaceuticals Corp TKMR other info.
http://investorshangout.com/Tekmira-Pharmaceu...KMR-55651/
TKMR Tekmira Pharmaceuticals Corp Recent Headline News
Tekmira Announces Licensing and Collaboration Agreement With Dicerna
GlobeNewswire - Mon Nov 17, 7:00AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) a leading developer of RNA interference (RNAi) therapeutics, today announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program.
DRNA: 9.41 (+0.14), TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.88 (+0.27), JNJ: 108.27 (+0.11), BCRX: 10.18 (+0.11), NAVB: 1.23 (+0.07), CMRX: 33.50 (+1.26), SRPT: 15.25 (-0.07), NBS: 6.81 (+0.64), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), CEMP: 13.81 (+0.21), OMER: 19.30 (+0.32)
Tekmira to Present at Stifel Healthcare Conference
GlobeNewswire - Wed Nov 12, 6:15PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 12:35 - 1:05 pm (PT) / 3:35 pm - 4:05 pm (ET) in New York at The New York Palace Hotel.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 10.11 (-0.89), CMRX: 33.50 (+1.26), SRPT: 15.25 (-0.07), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09)
Why We Are Short Tekmira
Glaucus Research - at Seeking Alpha - Mon Nov 10, 9:48AM CST
Tekmira (NASDAQ: TKMR ) ("Tekmira" or the "Company"
is a Vancouver-based biopharmaceutical company focused on developing RNA-interference ("RNAi" delivery technology using the Company's proprietary lipid nanoparticle...
BCRX: 10.18 (+0.11), TKMR: 17.07 (+0.66)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.70 (+0.10), ANET: 76.32 (-1.37), TKMR: 17.07 (+0.66), ORBC: 6.49 (+0.01), MDRX: 12.50 (+0.06), RMTI: 10.54 (+0.02), CTIC: 2.15 (+0.02), SHLD: 35.54 (-1.77), UBNT: 29.53 (-0.20), RIG: 25.72 (-0.33), KGC: 2.62 (-0.09), APT: 2.93 (+0.01), ANF: 29.01 (+0.11), MITK: 3.69 (+0.04), ZNGA: 2.65 (-0.12), CNET: 1.82 (-0.14), KING: 15.84 (-0.28), NETE: 1.33 (-0.09), SLXP: 101.03 (-1.29), RPRX: 9.32 (-0.02), NADL: 4.08 (-0.20), PGNX: 6.46 (+0.13), AVNR: 13.26 (+0.13), FSLR: 47.29 (-1.20), DVA: 75.46 (-0.20), NDLS: 23.25 (-0.23), ICPT: 156.10 (-6.48), AGIO: 84.37 (+0.31), PLNR: 7.02 (+0.33)
Tekmira tops 3Q revenue forecasts
Automated Insights - Fri Nov 07, 5:57AM CST
BURNABY, British Columbia (AP) _ Tekmira Pharmaceuticals Corp. (TKMR) on Friday reported a loss of $8.6 million, or 39 cents per share, in its third quarter.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
TEKMIRA PHARMACEUTICALS (TKMR) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Nov 07, 5:00AM CST
The following TEKMIRA PHARMACEUTICALS (TKMR) conference call took place on November 6, 2014, 05:00 PM ET. This is a transcript of that earnings call:
TKMR: 17.07 (+0.66)
Tekmira Pharmaceuticals' (TKMR) CEO Mark Murray on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:03PM CST
TKMR: 17.07 (+0.66)
Tekmira Pharmaceuticals misses by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 2:46PM CST
TKMR: 17.07 (+0.66)
Tekmira Provides Corporate Update and Announces Third Quarter 2014 Results
GlobeNewswire - Thu Nov 06, 2:30PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its financial and operating results for the third quarter ended September 30, 2014 and provided a corporate update.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Critical Alerts For Tesla Motors, Cheniere Energy, BroadSoft, Tekmira Pharmaceuticals and CBS Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TSLA, LNG, BSFT, TKMR and CBS.
TSLA: 253.18 (-5.50), LNG: 70.92 (-0.94), TKMR: 17.07 (+0.66), BSFT: 27.50 (unch), CBS: 53.07 (-0.34)
Tekmira to Host Analyst Day on November 21 in New York City
GlobeNewswire - Wed Nov 05, 6:21PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it will be hosting an Analyst and Investor Day on Friday, November 21, 2014 in New York City, NY. The presentations will be held between 9 a.m. - 1 p.m. Eastern Time (6 a.m. - 10 a.m. Pacific Time).
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Connecting The Dots: Ebola Plays To Oil, Airlines, Gold, REMs, And Uranium
InvestorsGuru - Seeking Alpha - Thu Oct 30, 2:52PM CDT
Ebola Infects Stock Market Three-Peat I tend to be a contrarian value investor which means I mostly buy quality stocks that are beaten down and out of favour. These stocks are often longer-term turnaround plays with established products, sales,...
CCJ: 18.95 (+0.05), AA: 16.80 (-0.14), GDXJ: 26.30 (-0.05), APT: 2.93 (+0.01), GLD: 113.68 (-0.79), LAKE: 11.33 (+0.27), TKMR: 17.07 (+0.66), AAL: 43.97 (-0.04), SLV: 15.43 (-0.20), MCP: 1.22 (-0.03), GDX: 18.88 (-0.14), FLWS: 8.76 (-0.23)
Lakeland Industries And Sharps Compliance Announce Spikes In Revenue From Ebola Threat
Edward Vranic, CFA - at Seeking Alpha - Thu Oct 30, 3:39AM CDT
APT: 2.93 (+0.01), SMED: 4.26 (-0.12), LAKE: 11.33 (+0.27), VSR: 2.97 (-0.02), TKMR: 17.07 (+0.66)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.46 (+0.20), VRX: 134.89 (+0.68), ACT: 248.25 (+4.48), AMGN: 158.68 (+1.00), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), AGN: 209.86 (+11.21), JNJ: 108.28 (+0.12), SHPG: 204.54 (+1.92), MRK: 59.61 (+0.54), INFI: 14.23 (+0.13), ABBV: 65.27 (+1.27), KPTI: 40.49 (+0.72)
5 Stocks To Consider When Playing Ebola
Belopps Research - at Seeking Alpha - Wed Oct 29, 10:31AM CDT
INO: 10.11 (-0.89), SRPT: 15.25 (-0.07), NLNK: 31.32 (+0.78), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 10.11 (-0.89), MRK: 59.61 (+0.54), PFE: 29.98 (-0.36), SRPT: 15.25 (-0.07), NLNK: 31.32 (+0.78), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), NVS: 94.33 (+0.38)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.18 (+0.11), VSR: 2.97 (-0.02), TKMR: 17.07 (+0.66), NNVC: 3.26 (-0.13), INO: 10.11 (-0.89), CMRX: 33.50 (+1.26), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.25 (-0.07), SMED: 4.26 (-0.12), NLNK: 31.32 (+0.78), PLX: 2.08 (-0.01), LAKE: 11.33 (+0.27), NSPH: 0.44 (unch)
These Ebola Stocks are In Play This Week
ACCESSWIRE - Mon Oct 27, 4:11PM CDT
Coral Gables, FL / ACCESSWIRE / October 27, 2014 / Novavax, Inc. (NASDAQ: NVAX) announced that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8thVaccine and ISV Conference in Philadelphia on Sunday, October 26. Dr. Smith's presentation was titled: 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross-Neutralized 1976 Virus GP Pseudovirus.
NVAX: 5.09 (-0.19), TKMR: 17.06 (+0.65)
Recent News posted below.
Tekmira Pharmaceuticals Corp TKMR other info.
http://investorshangout.com/Tekmira-Pharmaceu...KMR-55651/
TKMR Tekmira Pharmaceuticals Corp Recent Headline News
Tekmira Announces Licensing and Collaboration Agreement With Dicerna
GlobeNewswire - Mon Nov 17, 7:00AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) a leading developer of RNA interference (RNAi) therapeutics, today announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program.
DRNA: 9.41 (+0.14), TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 22.88 (+0.27), JNJ: 108.27 (+0.11), BCRX: 10.18 (+0.11), NAVB: 1.23 (+0.07), CMRX: 33.50 (+1.26), SRPT: 15.25 (-0.07), NBS: 6.81 (+0.64), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), CEMP: 13.81 (+0.21), OMER: 19.30 (+0.32)
Tekmira to Present at Stifel Healthcare Conference
GlobeNewswire - Wed Nov 12, 6:15PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 12:35 - 1:05 pm (PT) / 3:35 pm - 4:05 pm (ET) in New York at The New York Palace Hotel.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Global Ebola Viral Infections Clinical Trials Report H2, 2014 - Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/wtw3b6/ebola_viral) has announced the addition of the "Ebola Viral Infections Global Clinical Trials Review, H2, 2014" report to their offering. Ebola Viral Infections Global Clinical Trials Review, H2, 2014" provides data on the Ebola Viral Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ebola Viral Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ebola Viral Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Tekmira Pharmaceuticals Corp. - Sarepta Therapeutics, Inc. - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Chimerix, Inc. Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Academy of Military Medical Sciences - University of Oxford For more information visit http://www.researchandmarkets.com/research/wt...bola_viral
INO: 10.11 (-0.89), CMRX: 33.50 (+1.26), SRPT: 15.25 (-0.07), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09)
Why We Are Short Tekmira
Glaucus Research - at Seeking Alpha - Mon Nov 10, 9:48AM CST
Tekmira (NASDAQ: TKMR ) ("Tekmira" or the "Company"
is a Vancouver-based biopharmaceutical company focused on developing RNA-interference ("RNAi" delivery technology using the Company's proprietary lipid nanoparticle... BCRX: 10.18 (+0.11), TKMR: 17.07 (+0.66)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.70 (+0.10), ANET: 76.32 (-1.37), TKMR: 17.07 (+0.66), ORBC: 6.49 (+0.01), MDRX: 12.50 (+0.06), RMTI: 10.54 (+0.02), CTIC: 2.15 (+0.02), SHLD: 35.54 (-1.77), UBNT: 29.53 (-0.20), RIG: 25.72 (-0.33), KGC: 2.62 (-0.09), APT: 2.93 (+0.01), ANF: 29.01 (+0.11), MITK: 3.69 (+0.04), ZNGA: 2.65 (-0.12), CNET: 1.82 (-0.14), KING: 15.84 (-0.28), NETE: 1.33 (-0.09), SLXP: 101.03 (-1.29), RPRX: 9.32 (-0.02), NADL: 4.08 (-0.20), PGNX: 6.46 (+0.13), AVNR: 13.26 (+0.13), FSLR: 47.29 (-1.20), DVA: 75.46 (-0.20), NDLS: 23.25 (-0.23), ICPT: 156.10 (-6.48), AGIO: 84.37 (+0.31), PLNR: 7.02 (+0.33)
Tekmira tops 3Q revenue forecasts
Automated Insights - Fri Nov 07, 5:57AM CST
BURNABY, British Columbia (AP) _ Tekmira Pharmaceuticals Corp. (TKMR) on Friday reported a loss of $8.6 million, or 39 cents per share, in its third quarter.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
TEKMIRA PHARMACEUTICALS (TKMR) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Nov 07, 5:00AM CST
The following TEKMIRA PHARMACEUTICALS (TKMR) conference call took place on November 6, 2014, 05:00 PM ET. This is a transcript of that earnings call:
TKMR: 17.07 (+0.66)
Tekmira Pharmaceuticals' (TKMR) CEO Mark Murray on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:03PM CST
TKMR: 17.07 (+0.66)
Tekmira Pharmaceuticals misses by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 2:46PM CST
TKMR: 17.07 (+0.66)
Tekmira Provides Corporate Update and Announces Third Quarter 2014 Results
GlobeNewswire - Thu Nov 06, 2:30PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its financial and operating results for the third quarter ended September 30, 2014 and provided a corporate update.
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Critical Alerts For Tesla Motors, Cheniere Energy, BroadSoft, Tekmira Pharmaceuticals and CBS Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TSLA, LNG, BSFT, TKMR and CBS.
TSLA: 253.18 (-5.50), LNG: 70.92 (-0.94), TKMR: 17.07 (+0.66), BSFT: 27.50 (unch), CBS: 53.07 (-0.34)
Tekmira to Host Analyst Day on November 21 in New York City
GlobeNewswire - Wed Nov 05, 6:21PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it will be hosting an Analyst and Investor Day on Friday, November 21, 2014 in New York City, NY. The presentations will be held between 9 a.m. - 1 p.m. Eastern Time (6 a.m. - 10 a.m. Pacific Time).
TKMR: 17.07 (+0.66), TKM.TO: 19.23 (+0.75)
Connecting The Dots: Ebola Plays To Oil, Airlines, Gold, REMs, And Uranium
InvestorsGuru - Seeking Alpha - Thu Oct 30, 2:52PM CDT
Ebola Infects Stock Market Three-Peat I tend to be a contrarian value investor which means I mostly buy quality stocks that are beaten down and out of favour. These stocks are often longer-term turnaround plays with established products, sales,...
CCJ: 18.95 (+0.05), AA: 16.80 (-0.14), GDXJ: 26.30 (-0.05), APT: 2.93 (+0.01), GLD: 113.68 (-0.79), LAKE: 11.33 (+0.27), TKMR: 17.07 (+0.66), AAL: 43.97 (-0.04), SLV: 15.43 (-0.20), MCP: 1.22 (-0.03), GDX: 18.88 (-0.14), FLWS: 8.76 (-0.23)
Lakeland Industries And Sharps Compliance Announce Spikes In Revenue From Ebola Threat
Edward Vranic, CFA - at Seeking Alpha - Thu Oct 30, 3:39AM CDT
APT: 2.93 (+0.01), SMED: 4.26 (-0.12), LAKE: 11.33 (+0.27), VSR: 2.97 (-0.02), TKMR: 17.07 (+0.66)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.46 (+0.20), VRX: 134.89 (+0.68), ACT: 248.25 (+4.48), AMGN: 158.68 (+1.00), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), AGN: 209.86 (+11.21), JNJ: 108.28 (+0.12), SHPG: 204.54 (+1.92), MRK: 59.61 (+0.54), INFI: 14.23 (+0.13), ABBV: 65.27 (+1.27), KPTI: 40.49 (+0.72)
5 Stocks To Consider When Playing Ebola
Belopps Research - at Seeking Alpha - Wed Oct 29, 10:31AM CDT
INO: 10.11 (-0.89), SRPT: 15.25 (-0.07), NLNK: 31.32 (+0.78), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 10.11 (-0.89), MRK: 59.61 (+0.54), PFE: 29.98 (-0.36), SRPT: 15.25 (-0.07), NLNK: 31.32 (+0.78), TKMR: 17.07 (+0.66), GSK: 45.83 (+0.09), NVS: 94.33 (+0.38)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.18 (+0.11), VSR: 2.97 (-0.02), TKMR: 17.07 (+0.66), NNVC: 3.26 (-0.13), INO: 10.11 (-0.89), CMRX: 33.50 (+1.26), APT: 2.93 (+0.01), HEB: 0.28 (+0.01), SRPT: 15.25 (-0.07), SMED: 4.26 (-0.12), NLNK: 31.32 (+0.78), PLX: 2.08 (-0.01), LAKE: 11.33 (+0.27), NSPH: 0.44 (unch)
These Ebola Stocks are In Play This Week
ACCESSWIRE - Mon Oct 27, 4:11PM CDT
Coral Gables, FL / ACCESSWIRE / October 27, 2014 / Novavax, Inc. (NASDAQ: NVAX) announced that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8thVaccine and ISV Conference in Philadelphia on Sunday, October 26. Dr. Smith's presentation was titled: 2014 Guinea Ebola Virus Recombinant Glycoprotein (GP) Nanoparticle Vaccine was Highly Immunogenic and Cross-Neutralized 1976 Virus GP Pseudovirus.
NVAX: 5.09 (-0.19), TKMR: 17.06 (+0.65)
(0)
(0)